<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene T19R;E156del;F157del;R158G;L452R;T478K;D614G;P681R;D950N literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.T19R;E156_F157del;R158G;L452R;T478K;D614G;P681R;D950N</span> literature reference collection</h1>
<div class="effect_section"><h2 id="ACE2_receptor_binding_affinity">ACE2 receptor binding affinity</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.2 aka Delta) showed a 2.34x increase  in binding (KD) relative to D614G. [exact variant list not provided in manuscript, is inferred and represents minimal set agreed upon commonly] (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_binding">Convalescent plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> This variant combination (representing lineage B.1.617.2 aka Delta) showed a 1.92x decrease in Spike binding (relative to D614G alone)  by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly] (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="outcome_hazard_ratio">Outcome hazard ratio</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In Ontario between Feb 7 and Jun 27, 2021, increased risk with the Delta variant was 108% (95% CI 78%–140%) for hospitalization,  235% (95% CI 160%–331%) for ICU admission and 133% (95% CI 54%–231%) for death.<br/> (<a href="https://doi.org/10.1503/cmaj.211248" class="lit_link">Fisman and Tuite (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> In the UK, of 43338 COVID-19-positive patients, 8682 had the Delta variant (median age 31 years [IQR 17–43]) and 196 were admitted to hospital within 14  days after the specimen was taken (adjusted hazard ratio [HR] 2.26 [95% CI 1.32–3.89] relative to Alpha cases). Being admitted to hospital or attending emergency care within 14 days for Delta cases had an adjusted HR 1.45 [95% CI 1.08–1.95] relative to Alpha. Most patients were unvaccinated (32 078 [74·0%] across both groups). The HRs for vaccinated patients were similar: 1.94 [95% CI 0.47–8.05] for hospitalization and 1.58 [0.69–3.61]) for hospital admission or  emergency care attendance.<br/> (<a href="https://doi.org/10.1016/S1473-3099(21)00475-8" class="lit_link">Twohig et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> In Denmark, for the period Jan 1 to Jun 27, 2021, Delta variant was associated with increased an risk ratio of 2.83 [95% CI 2.02–3.98] for hospitalization.<br/> (<a href="https://doi.org/10.1016/S1473-3099(21)00580-6" class="lit_link">Bager et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Infectious viral titers in lung tissue determined using a tissue culture infectious dose (TCID) assay in 10 hamsters showed that Delta Molnupiravir (MK-4482) had ~4x fold drop.<br/> (<a href="https://doi.org/10.1172/jci.insight.160108" class="lit_link">Rosenke et al. (2022)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_efficacy">Vaccine efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 2027 test-positive cases were Delta.<br/>Two dose vaccine efficacy against Delta decreased from 94.1% (90.5-96.3%) 14-60 days after vaccination to 80.0%  (70.2-86.6%) 151-180 days after vaccination. Waning was less pronounced for non-Delta variants. VE against Delta  was lower among individuals aged ≥65 years (75.2% [59.6-84.8%]) than those aged 18-64 years (87.9% [85.5-89.9%]). <br/> VE against Delta hospitalization was 97.6% (92.8-99.2%). One-dose VE was 77.0% (60.7-86.5%) against Delta infection.<br/> (<a href="https://doi.org/10.1101/2021.09.29.21264199" class="lit_link">Bruxvoort et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> In Minnesota in July 2020 (when Delta variant prevalence was >70%), the effectiveness against infection for mRNA-1273 was estimated at 76%  (95% CI: 58-87%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.<br/>An even more pronounced reduction in effectiveness was observed for BNT162b2 of 42% (95% CI: 13-62%).  mRNA-1273 conferred a two-fold risk reduction against breakthrough infection compared to BNT162b2 (IRR = 0.50, 95% CI: 0.39-0.64).<br/>In Florida, which is currently experiencing its largest COVID-19 surge to date, the risk of infection in July after full vaccination  with mRNA-1273 was about 60% lower than after full vaccination with BNT162b2 (IRR: 0.39, 95% CI: 0.24-0.62). <br/> [variant list included is ancestral Delta, as this was an observational study no variant list was given]  (<a href="https://doi.org/10.1101/2021.08.06.21261707" class="lit_link">Puranik et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) with the delta variant was (30.7%; 95% confidence interval [CI], 25.2 to 35.7); the results were similar for both vaccines.<br/>With the BNT162b2 vaccine, the effectiveness of two doses was 88.0% (95% CI, 85.3 to 90.1) among those with the delta variant.  With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 67.0% (95% CI, 61.3 to 71.8) among those with the delta variant.<br/> (<a href="https://doi.org/10.1056/NEJMoa2108891" class="lit_link">Lopez Bernal et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> During December 14, 2020–August 14, 2021, frontline worker without previous documented SARS-CoV-2 infection were monitored regularly.<br/>Of 4,217 participants, 3,483 (83%) were vaccinated; 2,278 (65%) received Pfizer-BioNTech, 1,138 (33%) Moderna, and 67 (2%) Janssen  (Johnson & Johnson) COVID-19 vaccines.<br/>Adjusted VE during this Delta predominant period was 66% (95% CI = 26%–84%) compared with 91% (95% CI = 81%–96%) during the  months preceding Delta predominance.<br/>This trend should be interpreted with caution because VE might also be declining as time since vaccination increases and because of  poor precision in estimates due to limited number of weeks of observation and few infections among participants. As with all observational VE  studies, unmeasured and residual confounding might be present.<br/> (<a href="https://doi.org/10.15585/mmwr.mm7034e4" class="lit_link">Fowlkes et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> 136,160 reports from 14,997 nursing care facilities were broken into pre-Delta (Mar 1-May 9, 2021), intermediate (May 10-Jun 20, 2021)  and Delta (Jun 21-Aug 1, 2021).<br/>Two doses of mRNA vaccines were 74.7% effective against infection among nursing home residents early in the vaccination program  (March–May 2021). During June–July 2021, when B.1.617.2 (Delta) variant circulation predominated, effectiveness declined significantly to 53.1%.<br/> (<a href="https://doi.org/10.15585/mmwr.mm7034e3" class="lit_link">Nanduri et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Using a test-negative design using Ontario data between Dec 14, 2020 and May 30, 2021, 421,073 symptomatic community-dwelling individuals were tested.<br/>Against Delta, vaccine effectiveness after partial vaccination tended to be lower compared to Alpha for mRNA-1273 (72% vs. 83%) and BNT162b2 (56% vs. 66%),  but was similar to Alpha for ChAdOx1 (67% vs. 64%). Full vaccination with BNT162b2 increased protection against Delta (87%) to levels comparable to .<br/>Alpha (89%) and Beta/Gamma (84%). Delta-positive cases were biased towards young male residents of the Peel region. (<a href="https://doi.org/10.1101/2021.06.28.21259420" class="lit_link">Nasreen et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Using a matched test-negative, case- control study design in Qatar, BNT162b2 effectiveness against any Delta infection, symptomatic or asymptomatic,  was 64.2% (95% CI: 38.1-80.1%) ≥14 days after the first dose and before the second dose, but was only 53.5% (95% CI: 43.9-61.4%) ≥14 days after the  second dose, in a population in which a large proportion of fully vaccinated persons received their second dose several months earlier.<br/>Corresponding effectiveness measures for mRNA-1273 were 79.0% (95% CI: 58.9-90.1%) and 84.8% (95% CI: 75.9-90.8%), respectively. Effectiveness against any severe, critical, or fatal COVID-19 disease due to Delta was 89.7% (95% CI: 61.0-98.1%) for BNT162b2 and 100.0% (95% CI: 41.2-100.0%) for  mRNA-1273, ≥14 days after the second dose.<br/>The lower VE in Qatar relative to those reported in some other jurisdictions such as the UK and Canada (75%+) may reflect waning of vaccine protection for  those who received their second dose by end of 2020 or early 2021. Risk perception and behaviour amongst vaccinated individuals opver time may also  play a role.<br/> (<a href="https://doi.org/10.1101/2021.08.11.21261885" class="lit_link">Tang et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Of 218 individuals with B.1.617.2 infection in Singapore, 84 had received a mRNA vaccine of which 71 were fully vaccinated,  130 were unvaccinated and 4 received a non-mRNA. Despite significantly older age in the vaccine breakthrough group, the odds of  severe COVID-19 requiring oxygen supplementation was significantly lower following vaccination (adjusted odds ratio 0.07 95%CI: 0.015-0.335, p=0.001).<br/> (<a href="https://doi.org/10.1101/2021.07.28.21261295" class="lit_link">Chia et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> The incidence rate of Covid-19 during the Delta-dominant period (Jul-Aug 2021) was lower for late vaccinated (49.0/1000 person-years) [formerly placebo]  versus early vaccinated (77.1/1000 person-years) participants in the Moderna mRNA-1273 Phase 3 trials, representing a 36.4% VE reduction (95% CI 17.1%-51.5%).<br/>There were fewer severe Covid-19 cases in the late group (6; 6.2/1000 person-years) than early (13; 3.3/1000 person-years), representing a 46.0%  reduction (95% CI −52.4%-83.2%). Three Covid-19 related hospitalizations occurred with two resulting deaths in the early group.<br/> (<a href="https://doi.org/10.1101/2021.09.17.21263624" class="lit_link">Baden et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Case 62541 cluster in Singapore included a fully vaccinated nurse 2 months post-vaccine [likely Pfizer based on dates and supply],  and a doctor of unknown vaccine status. This cluster was caused by a B.1.617.2 virus [via crossreference to  https://www.moh.gov.sg/docs/librariesprovider5/default-document-library/annex-a65c38244a9e142828ce500c88a5a5503.pdf].<br/> (<a href="https://www.moh.gov.sg/news-highlights/details/3-new-cases-of-locally-transmitted-covid-19-infection-28apr2021-update" class="lit_link">Singapore MOH (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> 2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript] (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Vaccination of health care workers in Delhi was started in early 2021, with the ChdOx-1 (Astra Zeneca) vaccine. Surveillance has suggested B.1.1.7 dominance in the Delhi area during early 2021, with growth of B.1.617 since March 2021. During the wave of infections during March and April an outbreak of SARS-CoV-2 was confirmed in 33 vaccinated staff  members at a single tertiary centre (age 27-77 years). Sequencing revealed that 16/33 were B.1.617.2, with a range of other B lineage viruses including B.1.1.7 for the rest except one A lineage case.<br/>Importantly no severe cases were documented in this event. (<a href="https://doi.org/10.1101/2021.05.08.443253" class="lit_link">Ferreira et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccinee_plasma_binding">Vaccinee plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> This variant combination (representing lineage B.1.617.2 aka Delta) showed a 1.64x decrease in Spike binding (relative to D614G alone)  by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  <br/> 1.89x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.<br/> [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly] (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
